Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Arcus Biosciences, Inc. Common Stock
(NY:
RCUS
)
21.48
-0.32 (-1.47%)
Streaming Delayed Price
Updated: 1:51 PM EST, Jan 20, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Arcus Biosciences, Inc. Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Arcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation Programs
January 07, 2026
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences President Sells $2 Million as Stock Delivers 48% Annual Return
↗
January 05, 2026
Arcus Biosciences, a clinical-stage oncology innovator, reported significant insider selling as its stock capped a strong one-year return.
Via
The Motley Fool
Topics
Regulatory Compliance
Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare Conference
December 18, 2025
From
Arcus Biosciences
Via
Business Wire
Why Did Arcus Biosciences Stock Slump 10% Today?
↗
December 12, 2025
Arcus will stop testing a domvanalimab-based drug combination in upper gastrointestinal cancers after independent reviewers found the treatment did not improve survival.
Via
Stocktwits
Analyst Expectations For Arcus Biosciences's Future
↗
October 29, 2025
Via
Benzinga
Arcus Biosciences Turns Heads With 26.7-Month Survival In Gastric Cancer Study — Retail Calls It ‘Unprecedented’
↗
October 12, 2025
Via
Stocktwits
Earnings Scheduled For August 6, 2025
↗
August 06, 2025
Via
Benzinga
Arcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunology Portfolio
December 12, 2025
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
December 09, 2025
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
November 18, 2025
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences President Sells $2 Million in Stock Under Trading Plan
↗
November 02, 2025
Arcus Biosciences President Sells $2 Million in Stock Under Trading Plan
Via
The Motley Fool
Topics
Regulatory Compliance
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
October 30, 2025
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences Announces Commencement of Public Offering of Common Stock
October 30, 2025
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update
October 28, 2025
From
Arcus Biosciences
Via
Business Wire
Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia
October 19, 2025
From
Arcus Biosciences
Via
Business Wire
Gilead Sciences/Arcus Biosciences' Investigational Cancer Drug Shows Overall Survival Of Around 27 Months
↗
October 13, 2025
Arcus Biosciences reports 26.7-month median survival and 59% response rate in Phase 2 cancer study with domvanalimab combination therapy.
Via
Benzinga
Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric Study
October 12, 2025
From
Arcus Biosciences, Inc.
Via
Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
October 09, 2025
From
Arcus Biosciences
Via
Business Wire
How Arcus Biosciences Aims To Take On Merck In Cancer Treatment
↗
October 07, 2025
Shares climbed Tuesday as enthusiasm grows for the biotech company's experimental cancer drug.
Via
Investor's Business Daily
Why Is Arcus Biosciences Stock Trading Higher On Monday?
↗
October 06, 2025
Arcus Biosciences reports casdatifan monotherapy data in renal cancer, showing a 35% response rate and median progression-free survival not yet reached.
Via
Benzinga
Arcus Biosciences Presents New Data for its HIF-2a Inhibitor Casdatifan and Discloses First Inflammation Programs at Investor Event
October 06, 2025
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
September 24, 2025
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
September 08, 2025
From
Arcus Biosciences
Via
Business Wire
Macy's Increases FY2025 Outlook, Joins REV Group, HealthEquity, Alphabet and Wellness And Other Big Stocks Moving Higher On Wednesday
↗
September 03, 2025
Via
Benzinga
Arcus Biosciences to Host Investor Event to Highlight its Late-Stage Casdatifan Program and Next Wave of Programs Focused on Inflammation
September 02, 2025
From
Arcus Biosciences
Via
Business Wire
Arcus Biosciences to Participate in Three Upcoming Investor Conferences
August 20, 2025
From
Arcus Biosciences
Via
Business Wire
Jim Cramer Recommends This Energy Stock, But Don't 'Bank It All' On Arcus
↗
August 14, 2025
On CNBC's Mad Money Lightning Round, Jim Cramer endorsed buying Uranium Energy and called Arcus Biosciences a speculative play.
Via
Benzinga
Gilead Lifts Annual Outlook As Yeztugo Launch Nears
↗
August 08, 2025
Gilead raised its 2025 earnings and sales outlook after posting better-than-expected Q2 results, led by strong HIV and oncology drug sales.
Via
Benzinga
Arcus (RCUS) Q2 Revenue Jumps 310%
↗
August 06, 2025
Via
The Motley Fool
Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update
August 06, 2025
From
Arcus Biosciences
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
